Present clinical studies of active immunotherapy for malignancies using dendritic cells (DCs)
require elucidation of the sites where DCs localize after injection. We evaluated the pattern …

The potential of α-particle emitters to treat cancer has been recognized since the early 1900s.
Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry…

α-Particle–emitting radionuclides, such as 211 At, with a 7.2-h half-life, may be optimally
suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as …

PURPOSE: To assess the efficacy and toxicity of intraresection cavity 131 I-labeled murine
antitenascin monoclonal antibody 81C6 and determine its true response rate among patients …

TP-38 is a recombinant chimeric targeted toxin composed of the EGFR binding ligand TGF-α
and a genetically engineered form of the Pseudomonas exotoxin, PE-38. After in vitro and …

Purpose To assess the efficacy and toxicity of intraresection cavity iodine-131–labeled murine
antitenascin monoclonal antibody 81C6 ( 131 I-m81C6) among recurrent malignant brain …

The purpose of this study is to determine the maximum tolerated dose (MTD), dose-limiting
toxicity (DLT), and intracerebral distribution of a recombinant toxin (TP-38) targeting the …

This paper investigates the potential of magnetic resonance imaging (MRI) to improve the
estimation of within-tumor variations in F18-FDG concentration. An image model is described …

Purpose: To determine the maximum-tolerated dose (MTD) of iodine 131 (' 3 11)-labeled
81C6 monoclonal antibody (mAb) in brain tumor patients with surgically created resection …

Although nanomedicines have been pursued for nearly 20 years, fundamental chemical
strategies that seek to optimize both the drug and drug carrier together in a concerted effort …